We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-25.07%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$28M
Cap. Flow
+$4.28M
Cap. Flow %
3.37%
Top 10 Hldgs %
74.71%
Holding
39
New
7
Increased
11
Reduced
6
Closed
15

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$8.49M
2
ONEM
1Life Healthcare
ONEM
+$6.23M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$5.87M
4
THC icon
Tenet Healthcare
THC
+$3.53M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$2.98M

Top Sells

Rank Stock Value
1
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$4.89M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.71M
3
AGL icon
Agilon Health
AGL
+$3.55M
4
EHC icon
Encompass Health
EHC
+$2.84M
5
OSCR icon
Oscar Health
OSCR
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 97.28%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
26
Alnylam Pharmaceuticals
ALNY
$36.3B
– –
-22,704
Closed -$3.71M
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.58B
– –
-34,000
Closed -$2.13M
EHC icon
28
Encompass Health
EHC
$11.2B
– –
-50,154
Closed -$2.84M
LKFT
29
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-195,000
Closed -$12.1M
GMED icon
30
Globus Medical
GMED
$10.4B
– –
-18,000
Closed -$1.33M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$2.23B
– –
-20,000
Closed -$333K
NEO icon
32
NeoGenomics
NEO
$1.81B
– –
-63,524
Closed -$772K
OGN icon
33
PUT
Organon & Co
OGN
$3.55B
– –
-20,000
Closed -$699K
OSCR icon
34
Oscar Health
OSCR
$8.5B
– –
-237,500
Closed -$2.37M
SEM
35
DELISTED
Select Medical
SEM
– –
-168,503
Closed -$2.18M
ACCD
36
DELISTED
Accolade Inc
ACCD
– –
-124,393
Closed -$2.18M
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
– –
-93,923
Closed -$292K
SIOX
38
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-670,300
Closed -$449K
CNVY
39
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
– –
-748,134
Closed -$4.89M
1
2

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2022 Portfolio in Review

As of Q2 2022, Prosight Management held 39 positions worth $127M, down 18% from $155M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Prosight Management deployed $4.28M of net new capital in Q2 2022, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was 1Life Healthcare: 725,000 shares worth $5.68M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $977K trimmed.

  • Prosight Management's largest Q2 2022 buy was 1Life Healthcare: 725,000 shares worth $5.68M.
  • Prosight Management added most to Kezar Life Sciences in Q2 2022, an estimated $8.49M increase.
  • Prosight Management's biggest Q2 2022 reduction was Charles River Laboratories, cutting an estimated $977K.
  • Prosight Management fully exited Convey Health Solutions Holdings, Inc. in Q2 2022, selling an estimated $4.89M.
  • Prosight Management's ten largest holdings make up 75% of its $127M portfolio in Q2 2022.
  • Prosight Management opened 7 new positions and closed 15 in Q2 2022.
  • Prosight Management's portfolio value fell 18% quarter-over-quarter to $127M.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.